Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Operating Leases Other Accumulated Expenses Other Non-Current Assets Payables Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Immucell (ICCC) Other Non-Current Liabilities (2016 - 2023)

Immucell's Other Non-Current Liabilities history spans 9 years, with the latest figure at $9.3 million for Q2 2023.

For Q2 2023, Other Non-Current Liabilities changed N/A year-over-year to $9.3 million; the TTM value through Jun 2023 reached $9.3 million, changed N/A, while the annual FY2019 figure was $58526.0, N/A changed from the prior year.
Other Non-Current Liabilities reached $9.3 million in Q2 2023 per ICCC's latest filing, down from $9.6 million in the prior quarter.
In the past five years, Other Non-Current Liabilities ranged from a high of $9.6 million in Q1 2023 to a low of $57216.0 in Q2 2019.